Over the last eight years, we’ve internally conducted over 2,500 calls with executives. We’ve also seen the internal process of many of the top fundamental equity hedge funds globally. While primary research can provide an edge when conducted correctly, it can be destructive when conducted poorly. IP Fieldwork is a free podcast that explores common mistakes, challenges and opportunities to improve the art and science of interviewing industry professionals.
You can follow IP Fieldwork on Spotify and Apple or add our feed to any podcast player here.
There are many biases and risks embedded within the process of interviewing industry executives. After 2,500+ calls, we’ve made every mistake possible. We’ve entered executive calls unprepared, framed questions to confirm our priors, and often found ourselves prey to authority bias. We’ve even caught ourselves regurgitating an executive’s view as our own. No one is immune from such biases. We regularly see similar mistakes by investors at top funds.
Poor primary research can hijack independent thinking. It leads to poor judgment. This is fatal in investing. While primary research is more art than science, we believe there are simple processes that investors can implement to improve outcomes. IP Fieldwork is an exploration of processes to help us all improve how we conduct primary research.
Our “Primary Research Methods” series shares details of mistakes we’ve made, how our process has evolved, and how to prevent making important errors when conducting executive calls. We will also share case studies on companies we’re studying, how we source executives, and our process of publishing primary research.
The most recent IP Fieldwork episodes are as follows:
This is the first episode in our "Primary Research Methods" podcast series exploring the art and science of primary research:
This episode focuses on common mistakes investors make when submitting research projects to expert networks. We explore:
This podcast provides insight into our research process behind our recent published work on Danaher's Cytiva bioprocessing business. We explore:
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research